INTEGRATION OF NON-INVASIVE ASSESSMENT OF METABOLIC SYNDROME, LIVER FIBROSIS AND ARTERIAL STIFFNESS ENHANCES CARDIOVASCULAR RISK STRATIFICATION: A COMPREHENSIVE STUDY.

Metabolic syndrome, liver steatosis, and subclinical atherosclerosis are interconnected conditions associated with cardiovascular disease (CVD). This study investigated the relationship between liver fibrosis (assessed via Fibroscan and serological scores) with arterial stiffness (measured by Arteriograph), carotid intima media thickness (CIMT) using ultrasound, and cardiometabolic risk factors in a cohort of 41 patients. The study evaluated the correlation between risk classifications obtained through the Systematic COronary Risk Evaluation 2 (SCORE2) diagram and these noninvasive parameters. Results demonstrated that patients with metabolic syndrome exhibited higher levels of arterial stiffness, CIMT, and liver stiffness. Moreover, these parameters correlated with elevated cardiovascular risk category determined by SCORE2. Traditional risk calculators often have limitations in assessing risk, making the integration of Fibroscan and Arteriograph valuable for refining cardiovascular risk assessment, particularly in individuals with metabolic syndrome where subclinical multiorgan damage is likely. This comprehensive approach aids in personalized risk stratification for improved clinical management. [ABSTRACT FROM AUTHOR]